Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Rhea-AI Summary

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, announced that Sean P. Bohen, M.D., Ph.D., CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 4:15 p.m. ET. A live webcast will be available on Olema's website and archived for 14 days.

Olema’s lead candidate, OP-1250, is currently under evaluation for its effectiveness in treating ER-positive, HER2-negative breast cancer in a Phase 1/2 clinical trial.

SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19^th Annual Global Healthcare Conference on Monday, September 13, 2021, at 4:15 p.m. ET (1:15 p.m. PT).

A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com

FAQ

What event will Olema Pharmaceuticals participate in on September 13, 2021?

Olema Pharmaceuticals will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021.

Who is the CEO of Olema Pharmaceuticals?

Sean P. Bohen, M.D., Ph.D., is the CEO of Olema Pharmaceuticals.

Where can I watch the Olema Pharmaceuticals presentation?

You can watch the Olema Pharmaceuticals presentation live on their website in the Investors & Media section.

What is Olema’s lead product candidate?

Olema's lead product candidate is OP-1250, which is being evaluated for treating ER-positive, HER2-negative breast cancer.

What type of company is Olema Pharmaceuticals?

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for women's cancers.